Use of 5-Alpha Reductase Inhibitors in Dermatology: A Narrative Review
Abstract Finasteride and dutasteride are 5-alpha reductase selective inhibitors (5ARIs). They were introduced as therapeutic agents for the treatment of benign prostatic hyperplasia in 1992 and 2002, respectively; finasteride has also been approved for the treatment of androgenetic alopecia since ea...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Adis, Springer Healthcare
2023-07-01
|
| Series: | Dermatology and Therapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s13555-023-00974-4 |
| _version_ | 1797769637160550400 |
|---|---|
| author | Mariana Escamilla-Cruz Mario Magaña Sabrina Escandón-Perez Omar Yaxmehen Bello-Chavolla |
| author_facet | Mariana Escamilla-Cruz Mario Magaña Sabrina Escandón-Perez Omar Yaxmehen Bello-Chavolla |
| author_sort | Mariana Escamilla-Cruz |
| collection | DOAJ |
| description | Abstract Finasteride and dutasteride are 5-alpha reductase selective inhibitors (5ARIs). They were introduced as therapeutic agents for the treatment of benign prostatic hyperplasia in 1992 and 2002, respectively; finasteride has also been approved for the treatment of androgenetic alopecia since early 2000. These agents inhibit the conversion of testosterone (T) to 5α-dihydrotestosterone (5α-DHT), limiting steroidogenesis and playing a crucial role in the physiological function of the neuroendocrine system. Therefore, it has been proposed that blocking androgen synthesis with the use of 5ARIs would be beneficial in the treatment of various diseases related to states of hyperandrogenism. This review describes the dermatological pathologies in which 5ARIs have been used as part of the treatment, evaluation of the efficacy, and knowledge of the safety profile. Specifically, we discuss the application of 5ARIs in androgenetic alopecia, acne, frontal fibrosing alopecia, hirsutism, and the implications of adverse events associated with its use to inform about the applications of 5ARIs in general dermatology practice. |
| first_indexed | 2024-03-12T21:11:56Z |
| format | Article |
| id | doaj.art-68e6244ad0e54864a6480b9ff4770662 |
| institution | Directory Open Access Journal |
| issn | 2193-8210 2190-9172 |
| language | English |
| last_indexed | 2024-03-12T21:11:56Z |
| publishDate | 2023-07-01 |
| publisher | Adis, Springer Healthcare |
| record_format | Article |
| series | Dermatology and Therapy |
| spelling | doaj.art-68e6244ad0e54864a6480b9ff47706622023-07-30T11:08:22ZengAdis, Springer HealthcareDermatology and Therapy2193-82102190-91722023-07-011381721173110.1007/s13555-023-00974-4Use of 5-Alpha Reductase Inhibitors in Dermatology: A Narrative ReviewMariana Escamilla-Cruz0Mario Magaña1Sabrina Escandón-Perez2Omar Yaxmehen Bello-Chavolla3Service of Dermatology, Hospital General de México Dr. Eduardo Liceaga, S. S. (Ministry of Health)Service of Dermatology, Hospital General de México Dr. Eduardo Liceaga, S. S. (Ministry of Health)Internal Medicine, Hospital Angeles LomasResearch Division, Instituto Nacional de GeriatríaAbstract Finasteride and dutasteride are 5-alpha reductase selective inhibitors (5ARIs). They were introduced as therapeutic agents for the treatment of benign prostatic hyperplasia in 1992 and 2002, respectively; finasteride has also been approved for the treatment of androgenetic alopecia since early 2000. These agents inhibit the conversion of testosterone (T) to 5α-dihydrotestosterone (5α-DHT), limiting steroidogenesis and playing a crucial role in the physiological function of the neuroendocrine system. Therefore, it has been proposed that blocking androgen synthesis with the use of 5ARIs would be beneficial in the treatment of various diseases related to states of hyperandrogenism. This review describes the dermatological pathologies in which 5ARIs have been used as part of the treatment, evaluation of the efficacy, and knowledge of the safety profile. Specifically, we discuss the application of 5ARIs in androgenetic alopecia, acne, frontal fibrosing alopecia, hirsutism, and the implications of adverse events associated with its use to inform about the applications of 5ARIs in general dermatology practice.https://doi.org/10.1007/s13555-023-00974-4AlopeciaFinasterideDutasteride5-Alpha reductase inhibitorsDermatology |
| spellingShingle | Mariana Escamilla-Cruz Mario Magaña Sabrina Escandón-Perez Omar Yaxmehen Bello-Chavolla Use of 5-Alpha Reductase Inhibitors in Dermatology: A Narrative Review Dermatology and Therapy Alopecia Finasteride Dutasteride 5-Alpha reductase inhibitors Dermatology |
| title | Use of 5-Alpha Reductase Inhibitors in Dermatology: A Narrative Review |
| title_full | Use of 5-Alpha Reductase Inhibitors in Dermatology: A Narrative Review |
| title_fullStr | Use of 5-Alpha Reductase Inhibitors in Dermatology: A Narrative Review |
| title_full_unstemmed | Use of 5-Alpha Reductase Inhibitors in Dermatology: A Narrative Review |
| title_short | Use of 5-Alpha Reductase Inhibitors in Dermatology: A Narrative Review |
| title_sort | use of 5 alpha reductase inhibitors in dermatology a narrative review |
| topic | Alopecia Finasteride Dutasteride 5-Alpha reductase inhibitors Dermatology |
| url | https://doi.org/10.1007/s13555-023-00974-4 |
| work_keys_str_mv | AT marianaescamillacruz useof5alphareductaseinhibitorsindermatologyanarrativereview AT mariomagana useof5alphareductaseinhibitorsindermatologyanarrativereview AT sabrinaescandonperez useof5alphareductaseinhibitorsindermatologyanarrativereview AT omaryaxmehenbellochavolla useof5alphareductaseinhibitorsindermatologyanarrativereview |